London Cancer
Head and Neck
Radiotherapy Protocol

June 2014
Head and Neck Squamous Carcinoma

**Cancer definition**

- Cancers of the upper aero-digestive tract, predominately squamous cell carcinomas:
  - Oral cavity
  - Oropharynx
  - Hypopharynx
  - Larynx
  - Nasopharynx
  - Paranasal sinuses
- Salivary gland tumours
- Associated level I-V cervical lymph nodes

**Indications**

- Radical radiotherapy may be used in:
  - Primary treatment for unresected cancers of the head and neck
  - Treatment of benign disease rarely e.g. recurrent inoperable salivary gland pleomorphic adenomas
- Post-operative radiotherapy (PORT) may be indicated:
  - For positive resection margins
  - For extra-capsular spread in lymph node metastases
  - If any two of the following factors are present, PORT is also indicated:
    - Close margins (<5mm)
    - Invasion of soft tissues such as skeletal muscle
    - ≥ 2 lymph nodes positive for metastatic spread
    - 1 lymph node region positive of metastatic spread
    - Involved node >3cm in size (≥ N2a disease)
    - Multicentric primary
    - Peri-neural invasion

The following factors should also be borne in mind when considering a patient for PORT but are of lesser importance:

- Lymphovascular invasion
- Poorly differentiated (grade 3) disease
- T3-4 disease
- Carcinoma in situ or dysplasia at the resection margins where further surgery would be difficult
- Carcinomas of the oral cavity
- In cases where there are uncertainties regarding the surgical or histopathological findings.

**PLUS**

- Performance status ≤2
- Clinical benefit from organ preservation or improved PTV coverage likely (consultant decision)

**Intent**

- Radical
**Timing**
- A patient's 1st treatment (IMRT or neo-adjuvant chemotherapy) to start within 31 days from referral to the service, or within 62 days from referral if the patient is on the 'two-week wait' pathway as per nationally set targets.
- Post-operative radiotherapy to start within 6 weeks of primary surgery wherever possible.

**Chemotherapy and EBRT/IMRT**

**Induction Chemotherapy**
- There is no level 1 evidence for an advantage to induction chemotherapy before chemoradiotherapy. It can be considered in the following situations:
  - Primary treatment of Nasopharyngeal Carcinoma (NPC)
  - Primary treatment of rapidly progressive disease where urgent treatment is required
    - Cisplatin/5FU should be used. TCF can be considered

**Chemo-radiotherapy (CRT)**
- Primary treatment of NPC in combination with neo-adjuvant/adjuvant chemotherapy
- Primary treatment of ≥T3 or node positive squamous cell carcinomas and may be considered in earlier disease if there are other high risk factors
- In addition to surgery in esthesioneuroblastoma
- Cisplatin should be used using either a 3-weekly, 4 weekly or weekly regimen

**Post-operative chemo-radiotherapy (POCRT) may be used in:**
- Incomplete resections
- Extra-capsular spread in lymph node metastases
- Soft tissue invasion
- Selected cases where risk is increased such as resected pN2c-3 disease, resected pT3-4 disease and where there is extensive peri-neural or lympho-vascular invasion
- Age less than 70 years, although 'Biological Age' should be considered
- Cisplatin should be used using either a 3-weekly, 4 weekly or weekly regimen

Cetuximab may be used when there are contraindications to Cisplatin-based chemoradiotherapy such as: renal failure, pre-existing peripheral neuropathy, hearing impairment.

**Essential investigations and information required prior to decision to treat for EBRT and chemotherapy**
- Performance Status assessment
- Height and Weight
- Clinical examination including Flexible Nasendoscopy (FNE)
- EUA and biopsy
- Operation note in post-operative cases
- Contrast-enhanced CT Chest
- Contrast-enhanced MRI/CT of Head and Neck
- Ultrasound Neck +/- Fine-Needle Aspiration of suspicious nodes
- Histology/cytology and Imaging review in Head and Neck MDT
- Full blood count, serum urea and electrolytes, liver function tests.
- Serum Haemoglobin should be optimised to >12g/dl prior to radical radiotherapy start.
- Dental assessment with any remedial work done before beam immobilisation shell is made.
• Nutritional assessment with Percutaneous Endoscopic Gastrostomy (PEG) or Radiologically Inserted Gastrostomy (RIG) insertion in patients who:
  o Have had >10% weight loss in the past 3 months and who are at risk of malnutrition
  o Have nodal involvement and will have > 6cm of mucosa irradiated to >40Gy
  o Will be treated with IMRT where weight loss during treatment may impact on dosimetry
• Specialist Speech and Language Assessment where swallowing may be impaired by the tumour or may become more impaired during therapy. Flexible-Endoscopic Evaluation of Swallowing (FEES) may be performed at baseline and repeated during treatment to assess the risk of aspiration.
• Young male patients for chemotherapy should be counselled regarding the risk of infertility and offered semen cryopreservation. Those considering semen storage must have appropriate tests for Hepatitis B, Hepatitis C and HIV.
• Male and female patients for chemotherapy should be counselled to use effective contraception during chemotherapy and for 6 months after.
• Patients for Cisplatin-based chemoradiotherapy must have:
  o Detailed history taking for potential contraindications such as pre-existing renal failure, peripheral neuropathy or partial deafness.
  o Creatinine Clearance, repeated prior to the next dose of Cisplatin if the calculated GFR drops below 60ml/min. Baseline EDTA-GFR if suspicion of reduced renal function on calculated GFR
  o Baseline Audiometry, repeated if there is change in hearing as clinically indicated.
• Patients for Platinum-Fluoropyrimidine Neoadjuvant Chemotherapy should also have:
  o Detailed cardiac history and ECG, with assessment of left ventricular function (MUGA or Echocardiogram) as clinically indicated.
  o Assessment and placement of a Peripherally Inserted Central Catheter (PICC)

Information for patients
• Site-specific information leaflets discussing the diagnosis, preparations for treatment, details of the planning process and potential side-effects of treatment should be given to the patient in the Head and Neck clinic
• Further information may be provided by the Clinical Nurse Specialist.
• Referral to Smoking and Alcohol Cessation services.

Consent
Required for all patients including concurrent chemotherapy/cetuximab if appropriate.

Radiotherapy booking form completed

Trials
• ARTDECO

Position/immobilisation
• Supine
• Immobilisation shell
• Head rest / Knee / Ankle Stocks may be used
• Lymphadenopathy and scars may be marked with wire.
• Mouth bite where it is possible to exclude either the upper or lower half of the mouth from the field e.g. carcinoma of the oral cavity, nasal cavity, ethmoid and maxillary sinuses
• Dentures should be removed unless their presence may reduce mucosal toxicity by acting as a mouth bite
• Shells should not be cut-out over:
  o Tumour extending close to the skin
Operation and biopsy scars
- Anterior commissure in larynx cancer

**Image acquisition**
- CT head and neck as per Scanning Level Protocol
- 1.25 - 2mm slices
- i.v. contrast may be considered
- PET-CT or MRI fusion may be used where the clinician feels it will help tumour volume delineation

**Volume delineation and nomenclature**
- Volumes delineated with aid of diagnostic MRI and CT.
- Clinician delineates GTV, CTV and PTV volumes plus additional/non standard OAR.
- If one positive node in level consider treating all nodes in that level.
- Before contouring identify which nodal levels to include and what dose they should receive whether radical, post op or prophylactic radiation dose;
- 1 cm bolus applied to regions of risk e.g. skin involvement.

**High dose GTV**
- Primary tumour and any involved lymph nodes. Use suffix indicating dose e.g. GTV65 (or v GTV65 if virtual volume i.e. following neo-adjuvant chemotherapy)
- For all tumour sites, outlining of this volume should be done with the aid of:
  - All diagnostic scans: MRI, PET, PET-CT and CT scans (including pre and post-operative imaging).
  - Operation notes (including EUA findings).
  - Clinical examination/ Nasendoscopy.
- If induction chemo used the high dose GTV should include pre-treatment tumour volume (Salama JK et al 2009)

**High dose CTV (including post operative CTV)**
- CTV\_dose = GTV\_dose + 10-20mm margin (e.g. CTV65)
- The risk of nodal extracapsular increases with size therefore a 1cm margin in nodes <20mm and 2cm margin if ≥20mm is suggested (Chao et al 2002).
- Sternocleidomastiod muscle should be included if there is extracapular spread in node adjacent to it
- Volume edited to incorporate areas of high risk (often the anatomical region where the tumour arose) and out of barriers to tumour spread (bone, fasciae) provided they are not breached.
- Air is not part of the CTV and, in principle, it should be edited out of the volume
- In the postoperative setting include residual tumour / positive margins if radical dose is required.
- Merge the primary and involved lymph node volumes to create one CTV i.e. CTV65

**High dose PTV**
- PTV\_dose = CTV\_dose + 3 to 5 mm (e.g PTV65), dependent on local audit of set up error

**Elective CTV**
- CTV to be treated to an elective dose. Differentiate between 'high dose microscopic dose' e.g. 60Gy and 'low dose microscopic dose' e.g. 54Gy. Use suffix to denote dose e.g. CTV60 or CTV54
- In patients receiving post-operative radiotherapy the high dose volume will include the anatomical sites at risk of residual disease in addition to the original areas involved.
- Consider sparing normal tissue structures such as superficial parotid in oropharynx/NPC
**Elective PTV**
- \( PTV_{dose} = CTV_{dose} + 3 \) to 5 mm (e.g. PTV65), dependent on local audit of set up error.

**DOSE / FRACTIONATION**

<table>
<thead>
<tr>
<th>Tumour type</th>
<th>IMRT</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>High dose PTV</td>
</tr>
<tr>
<td>Squamous cell carcinoma</td>
<td>60-70Gy / 30 - 35 daily fractions *</td>
</tr>
<tr>
<td>Adenocarcinoma</td>
<td></td>
</tr>
<tr>
<td>Adenoid cystic cell</td>
<td></td>
</tr>
<tr>
<td>Acinic cell</td>
<td></td>
</tr>
<tr>
<td>Mucoepidermoid</td>
<td></td>
</tr>
<tr>
<td>Undifferentiated Salivary duct</td>
<td></td>
</tr>
<tr>
<td>carcinomas</td>
<td></td>
</tr>
<tr>
<td>Pleomorphic adenoma</td>
<td>50-60Gy / 25-30 daily fractions</td>
</tr>
</tbody>
</table>

*Consider simultaneous boost to GTV 70Gy/33# (2.12Gy/#)

**Planning technique**

**3D-Conformal RT**
- Fields: Chosen to optimise dose coverage and respect normal tissue tolerance, single isocentre technique, avoid junctions though gross disease.
- Energy: 6MV photons

**Inverse planned IMRT**
- Fields: 5-9 co-planar fields
  - e.g. Gantry: 0°, 51°, 102°, 154°, 206°, 257°, 309°
- Energy: 6MV photons

**Dose requirements**
- \( PTV_{dose} \): Dose over 95% prescribed dose (62.7Gy) ≥ 99%
  - No more that 5% volume ≥105% dose
  - No more than 1% volume ≥107% dose

Hot spots outside the PTV not to exceed 105%

Deviation from these intended dose levels may be required e.g. to account for OAR DVH and will be made at clinicians discretion.

**Plan Approval**
- Clinician to review and approve the whole plan to assess patient details, laterality, target coverage and DVH, OAR DVH and hotspots outside PTV / unexpected cold spots

**Treatment technique**
- Refer to Local Work Instructions
**Treatment verification**

- MV Electronic Portal Imaging according to local work instructions
- Additional imaging/reassessment of dosimetry with repeat planning CT scan may be justified by the practitioner where:
  - There is likely to be considerable soft tissue change during treatment, such as that seen in bulky disease or where nutritional status is likely to be affected during therapy
  - There is evidence of increasingly poor setup and a decision needs to be made about re-planning

**On treatment review definition and schedule gap category for management of unscheduled interruptions**

- Weekly review by clinician, SALT, Dietician, RT nurse
- Weekly weight
- Weekly FBC (aim Hb ≥ 12g/dl) plus U&E and LFT’s if concurrent chemotherapy
- Continued review until the acute side-effects of treatment have settled
- Clinician to dictate detailed end of treatment summary letter for NHM notes, GP and referring hospital patient notes
- Baseline post-treatment contrast-enhanced MRI/CT or PET scan at 3 months following radiotherapy completion

**GAP CATEGORY FOR MANAGEMENT OF UNSCHEDULED INTERRUPTIONS**

Classified as category 1:

- Category 1 patients will be offered treatment, as detailed below, to prevent prolongation of treatment schedules over Bank Holidays, with the exception of the aforementioned dates.

- **Single bank holidays**
  - When the holiday falls on a Monday patients should ideally be treated on the day or on the previous Saturday (to avoid a 3-day gap).

- **Two day bank holidays**
  - Treat on one holiday and the following (or previous) Saturday.

- **Christmas / New Year Period**
  - This period will require a combination of Bank Holiday and Saturday working to be agreed depending on the actual holidays on any particular year. The decision of which days to offer treatment during this period must be presented at Oncology Multi-Professional Meeting well before Christmas.
References

- Gregoire Et Al. CT- based delineation of lymph node levels and related CTVs in the node negative neck: DAHANCA, EORTC, GORTEC, NCIC, RTOG Consensus Guidelines. Radiotherapy And Oncology 69 (2003) 227- 236


